Transcatheter aortic valve replacement in a patient with renal cell carcinoma. A case report Case report
Article Sidebar
Main Article Content
Abstract
The transcatheter aortic valve replacement (TAVR) is an important therapy for symptomatic patients with severe aortic stenosis who have an intermediate or high surgical risk. The profile of patients eligible for this therapy as first choice has changed over the last few years, with increasing indication even for patients who do not have surgical high risk. Severely ill and frail patients, elderly or patients with multiple clinical comorbidities, such as cancer might be considered for TAVR.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Schofer N. Transcatheter Aortic Valve Replacement in Oncology Patients: Does it Make Sense? JACC Cardiovasc Interv. 2019; 12(1): 87-9.
3. Berkovitch A, Guetta V, Barbash IM et al. Favorable Short-Term and Long-Term Outcomes Among Patients With Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation. J Invasive Cardiol. 2018; 30(3): 105-9.
4. Baumgartner H, Falk V, Bax JJ et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739-91.
5. Mack MJ, Leon MB, Thourani VH et al; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019; 380(18): 1695-705.
6. Watanabe Y, Kozuma K, Hioki H et al. Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Versus Without Active Cancer. Am J Cardiol. 2016; 118(4): 572-7.
7. Landes U, Iakobishvili Z, Vronsky D et al. Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis. JACC Cardiovasc Interv. 2019; 12(1): 78-86.
8. Mangner N, Woitek FJ, Haussig S et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. J Interv Cardiol. 2018; 31(2): 188-96.
9. Reardon MJ, Van Mieghem NM, Popma JJ et al; SURTAVI Investigators. Surgical or Transcatheter Aortic Valve Replacement in Intermediate Risk Patients. N Engl J Med. 2017; 376(14): 1321-31.
10. Bourantas CV, Serruys PW. Evolution of transcatheter aortic valve replacement. Circ Res. 2014; 114(6): 1037-51.
11. Nishimura RA , Otto CM, Bonow RO et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 70(2): 252-89.